The Food and Drug Administration has approved a new imaging agent to detect prostate cancer after it has spread to other parts of the body.
Experts say the tracer, made by medical imaging company Lantheus, will give doctors an important visual aid to guide them to metastatic prostate cancer cells that, before now, were difficult to spot.